H.C. Wainwright raised the firm’s price target on ImmunoGen to $26 from $21 and keeps a Buy rating on the shares post the Q2 results. The analyst says the “impressive” revenue bodes well for Elahere’s growth.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IMGN: